Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteers

NCT01784536 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Single-Dose IV Oritavancin Diphosphate

Sponsor

Melinta Therapeutics, Inc.